Sumitomo Mitsui Trust Group Inc. Buys 79,724 Shares of Kenvue Inc. $KVUE

Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Kenvue Inc. (NYSE:KVUE) by 1.7% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,861,654 shares of the company’s stock after buying an additional 79,724 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned approximately 0.25% of Kenvue worth $101,754,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Pittenger & Anderson Inc. purchased a new stake in shares of Kenvue during the first quarter worth about $30,000. TruNorth Capital Management LLC bought a new position in Kenvue during the 1st quarter valued at approximately $36,000. Truvestments Capital LLC bought a new position in Kenvue during the 1st quarter valued at approximately $37,000. Trust Co. of Vermont lifted its holdings in Kenvue by 266.8% in the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock worth $33,000 after buying an additional 1,150 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd grew its position in shares of Kenvue by 378.5% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock worth $39,000 after buying an additional 1,287 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. UBS Group decreased their target price on Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft set a $18.00 price objective on shares of Kenvue in a research report on Friday. Zacks Research upgraded shares of Kenvue to a “strong sell” rating in a report on Monday, August 11th. Barclays cut their target price on shares of Kenvue from $20.00 to $17.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 1st. Finally, Evercore ISI decreased their price target on shares of Kenvue from $23.00 to $18.00 and set an “in-line” rating for the company in a research note on Tuesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $20.75.

Kenvue Stock Performance

Shares of KVUE stock opened at $15.00 on Friday. The company’s fifty day moving average price is $17.91 and its 200-day moving average price is $20.79. The stock has a market cap of $28.78 billion, a PE ratio of 20.26, a price-to-earnings-growth ratio of 2.16 and a beta of 0.72. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12 month low of $14.05 and a 12 month high of $25.17.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business had revenue of $3.84 billion for the quarter, compared to analysts’ expectations of $3.94 billion. During the same quarter in the prior year, the company earned $0.32 earnings per share. The business’s revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, equities analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were issued a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a yield of 5.5%. The ex-dividend date was Wednesday, August 13th. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio (DPR) is presently 112.16%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.